Document Detail

Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity.
Jump to Full Text
MedLine Citation:
PMID:  22504910     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effects of androgens on cardiovascular disease (CVD) risk in men remain unclear. To better characterize the relationship between androgens and HDL, we investigated the effects of testosterone replacement on HDL protein composition and serum HDL-mediated cholesterol efflux in hypogonadal men. Twenty-three older hypogonadal men (ages 51-83, baseline testosterone < 280 ng/dl) were administered replacement testosterone therapy (1% transdermal gel) with or without the 5α-reductase inhibitor dutasteride. At baseline and after three months of treatment, we determined fasting lipid concentrations, HDL protein composition, and the cholesterol efflux capacity of serum HDL. Testosterone replacement did not affect HDL cholesterol (HDL-C) concentrations but conferred significant increases in HDL-associated paraoxonase 1 (PON1) and fibrinogen α chain (FGA) (P = 0.022 and P = 0.023, respectively) and a decrease in apolipoprotein A-IV (apoA-IV) (P = 0.016). Exogenous testosterone did not affect the cholesterol efflux capacity of serum HDL. No differences were observed between men who received testosterone alone and those who also received dutasteride. Testosterone replacement in older hypogonadal men alters the protein composition of HDL but does not significantly change serum HDL-mediated cholesterol efflux. These effects appear independent of testosterone conversion to dihydrotestosterone. Further research is needed to determine how changes in HDL protein content affect CVD risk in men.
Authors:
Katya B Rubinow; Tomas Vaisar; Chongren Tang; Alvin M Matsumoto; Jay W Heinecke; Stephanie T Page
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2012-04-13
Journal Detail:
Title:  Journal of lipid research     Volume:  53     ISSN:  0022-2275     ISO Abbreviation:  J. Lipid Res.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-11     Completed Date:  2013-02-26     Revised Date:  2014-04-14    
Medline Journal Info:
Nlm Unique ID:  0376606     Medline TA:  J Lipid Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1376-83     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cholesterol, HDL / blood,  metabolism*
Fasting
Humans
Hypogonadism / blood,  drug therapy*,  metabolism
Male
Middle Aged
Proteome / drug effects*
Testosterone / administration & dosage,  pharmacology,  therapeutic use*
Grant Support
ID/Acronym/Agency:
DK-017047/DK/NIDDK NIH HHS; P01-HL-092969/HL/NHLBI NIH HHS; P01-HL-112625/HL/NHLBI NIH HHS; P30-DK-017047/DK/NIDDK NIH HHS; P30-DK-035816/DK/NIDDK NIH HHS; P50-CA-097186/CA/NCI NIH HHS; R01 AG037603/AG/NIA NIH HHS; R01 HL055362/HL/NHLBI NIH HHS; R01 HL112625/HL/NHLBI NIH HHS; R01-AG-037603/AG/NIA NIH HHS; R01-HL-086798/HL/NHLBI NIH HHS; R01-HL-089504/HL/NHLBI NIH HHS; T32 DK007247/DK/NIDDK NIH HHS; T32-DK-007247/DK/NIDDK NIH HHS; U54 HD042454/HD/NICHD NIH HHS; U54-HD-42454/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Proteome; 3XMK78S47O/Testosterone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): J Lipid Res
Journal ID (iso-abbrev): J. Lipid Res
Journal ID (publisher-id): jlr
ISSN: 0022-2275
ISSN: 1539-7262
Publisher: The American Society for Biochemistry and Molecular Biology
Article Information

open-access:
Received Day: 2 Month: 3 Year: 2012
Revision Received Day: 9 Month: 4 Year: 2012
epub-ppub publication date: Month: 7 Year: 2012
Print publication date: Month: 7 Year: 2012
Volume: 53 Issue: 7
First Page: 1376 Last Page: 1383
PubMed Id: 22504910
ID: 3371249
Publisher Id: p026005
DOI: 10.1194/jlr.P026005

Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity[S]
Katya B. Rubinow1*
Tomas Vaisar
Chongren Tang
Alvin M. Matsumoto§**
Jay W. Heinecke
Stephanie T. Page*
*Center for Research in Reproduction and Contraception, Department of Medicine, University of Washington School of Medicine, Seattle, WA
Diabetes and Obesity Center of Excellence, Division of Metabolism, Endocrinology, and Nutrition, and Department of Medicine, University of Washington School of Medicine, Seattle, WA
§Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA
**the Geriatric Research, Education, and Clinical Center, V. A. Puget Sound Health Care System, Seattle, WA
1To whom correspondence should be addressed.  e-mail: rubinow@uw.edu

Men exhibit an increased risk of cardiovascular disease (CVD) relative to premenopausal women (1), and it has been postulated that testosterone contributes to this elevated risk (2). Exogenous testosterone administration can decrease serum concentrations of HDL cholesterol (HDL-C) (2). Because low HDL-C correlates with increased CVD risk, this decrease could contribute to the presumed adverse cardiovascular effects of testosterone. In contrast, recent data demonstrate that low circulating androgen levels in men are associated with increased risk of CVD and mortality (3, 4), challenging the assumption that testosterone adversely impacts cardiovascular health in men.

Part of this apparent discrepancy regarding the impact of androgens on CVD may derive from the historical focus on HDL-C concentration as the sole indicator of HDL-associated CVD risk. Notably, recent intervention trials have failed to demonstrate CVD risk reduction with pharmacologic therapies that raise HDL-C. The cholesterol ester transfer protein (CETP) inhibitor torcetrapib substantially raised HDL-C but was associated with increased incidence of cardiovascular events and mortality (5). Similarly, niacin conferred a significant increase in HDL but failed to reduce cardiovascular event rate, leading to early termination of the Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial (6).

Because raising HDL-C does not uniformly appear to reduce CVD risk, recent investigations have focused on alternative methods to assess HDL function and composition, as these may prove more reliable indicators of differential risk or risk modification (7, 8). HDL particles comprise a complex assembly of lipid and protein components. We recently have demonstrated that HDL protein composition differs in populations with and without CVD (9, 10), and these differences in protein cargo likely affect HDL function. HDL particles play a pivotal role in the atheroprotective processes of endothelial repair and reverse cholesterol transport (1113). Endothelial cells generate the anti-inflammatory and vasodilatory signaling molecule nitric oxide (NO) through eNOS activity, which is stimulated by HDL-associated apolipoprotein A-I (apoA-I) and possibly sphingosine-1 phosphate (S1P) (14). Reverse cholesterol transport describes the process by which HDL transports cholesterol from peripheral tissues to the liver, including removal of cholesterol from foam cells within the artery wall (11). In vitro, efflux of cholesterol from macrophages by serum HDL is lower in individuals with established coronary artery disease (CAD). Importantly, HDL efflux capacity may be a better predictor of CAD than HDL-C alone (7). Thus, assessment of HDL protein composition and function are proving important strategies for enhancing our understanding of the relationship between HDL and CVD risk.

To provide further insights into the effects of testosterone on HDL and atherogenesis in men, we examined the impact of testosterone replacement on HDL function and composition. Previously, we performed a double-blind, randomized intervention trial in older hypogonadal men to evaluate the effects of testosterone replacement, with or without the 5α-reductase inhibitor dutasteride, on the prostate (15). We used a subset of fasting samples from this study to perform a secondary analysis examining the effects of testosterone therapy on HDL cholesterol efflux capacity and protein composition in hypogonadal men.


MATERIALS AND METHODS
Study protocol

Older men (age ≥ 50 years) with low baseline testosterone levels (≤280 ng/dl or ≤300 ng/dl on two separate occasions) were recruited as described previously (15). Exclusion criteria included history of prostate cancer; use of either androgen or anti-androgen therapy within the prior year; severe systemic illness, including diabetes; and weight > 300 lbs. The Institutional Review Board of the University of Washington approved all study procedures, and informed consent was obtained from all subjects.

Subjects were randomized to receive daily 7.5 g transdermal 1% testosterone gel (AndroGel 1%; Abbott Laboratories, Abbott Park, IL) with daily oral placebo (T-only) or 0.5 mg dutasteride (T+D) (Avodart; GlaxoSmithKline, Philadelphia, PA) to selectively decrease serum dihydrotestosterone (DHT). Testosterone dosing was adjusted to achieve physiologic serum concentrations (500–1,000 ng/dl) as described previously (15). Fasting blood for lipid analyses was obtained at baseline and at the three-month study visit. Forty-six subjects completed all study procedures, and 23 subjects (11 T-only, 12 T+D) were included in the present analysis on the basis of i) sufficient sample availability at desired time points, ii) achievement of serum testosterone level > 300 ng/dl at three months, and iii) exclusion of subjects on niacin or fibrate therapy.

Laboratory assessments

Serum sex steroids were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS), and gonadotropins and sex hormone binding globulin (SHBG) were assessed by immunofluorometric assay (15). Free testosterone was calculated using the Södergard equation (16). Fasting serum lipids were measured at the Northwest Lipid Research Center (Seattle, WA) using standard methods (17). Serum apoA-I levels were determined by nephelometry on a Siemens BN-II automated clinical instrument using a Siemens apoA-I reagent (18).

HDL protein composition

The HDL proteome was determined by LC-MS/MS as previously described (10, 19). Low abundance proteins (mean spectral count < 5 for >50% of subjects) were excluded from the final analysis, yielding a total of 42 HDL-associated proteins.

Serum HDL cholesterol efflux capacity

The cholesterol efflux capacity of apolipoprotein B (apoB)-depleted serum was determined with the method of Khera et al. (7), as previously described (19). The presented values reflect the fraction of total [3H] cholesterol released into the medium after subtraction of values obtained following serum-free incubation. Cholesterol efflux capacity was determined in a single assay from serum collected from all subjects at both time points. All samples were run in duplicate.

Statistical analysis

Comparisons at baseline and three months were made for both treatment groups (T-only, T+D) individually. As our principal aim was to investigate the impact of increased serum testosterone on HDL, we also performed comparisons on the entire study population to increase statistical power. Statistical analyses were performed using Prism 5 (GraphPad, La Jolla, CA). Comparisons between all values at baseline and three months were made using a Wilcoxon sign rank test. Comparisons between treatment groups were made using a Mann-Whitney test. Correlations were determined by calculating Spearman R values.

For analysis of changes in HDL-associated protein abundance, correction for multiple comparisons was performed using a modified Bonferoni method (20) based on Spearman R values and a threshold of 0.8. The adjusted threshold value for significance was P < 0.029. For all other analyses, P < 0.05 was considered statistically significant. To examine the potential interaction between statin use and testosterone replacement, spectral count data were normalized by log transformation, and 2-way ANOVA was performed.


RESULTS
Study participants

Of 53 subjects enrolled in the study, 46 completed all study procedures (15), and 23 were included in the present analysis. Thirty-one subjects had sufficient sample volume; 4 subjects were excluded due to serum testosterone levels < 300 ng/dl at month 3, and 4 were excluded due to concurrent niacin or fibrate therapy. Of the included subjects, 11 (4 T-only and 7 T+D) were not on lipid-lowering therapy, and 12 (7 T-only and 5 T+D) were on statin monotherapy. Selected subjects were representative of the overall study population with regard to age, weight, body mass index (BMI), and sex steroid levels (15) (supplementary Table I). Subjects had a baseline BMI of 32.2 ± 5 kg/m2, and no significant changes in body weight or BMI were evident over the study period. No serious adverse events occurred, and all safety data were reported previously (15).

Sex steroid concentrations

Among subjects in the present analysis, serum testosterone rose significantly, and levels in the physiologic range were achieved uniformly (Table 1). Estradiol levels also were significantly higher at three months compared with baseline. As expected, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production were suppressed with exogenous testosterone administration. No changes in SHBG or serum DHEA were observed. As anticipated, subjects who received dutasteride had significantly lower DHT levels than subjects who received testosterone alone. At three months, subjects in the T+D group also had higher serum estradiol levels than subjects in the T-only group, but the difference was not statistically significant (P = 0.21). As these differences could contribute to changes in HDL particle composition or function, subgroup and whole-group analyses were performed for all study measures.

Fasting lipid profiles and serum apoA-I

At baseline, fasting lipid levels across study subjects were notable for low HDL-C and mild hypertriglyceridemia (Table 2). No significant differences were found between the T-only and T+D groups at baseline or after three months of testosterone therapy. In both the subgroup and whole-group analyses, no changes in lipid profiles were observed after three months of testosterone therapy. Further, testosterone replacement with or without dutasteride coadministration did not alter serum concentrations of apoA-I.

HDL protein composition

As expected, apoA-I was the most abundant protein identified in HDL at both time points (21) and was unchanged with testosterone replacement (Table 3). In subgroup analysis, no significant differences in HDL-associated protein abundance were evident between the T-only and T+D groups, either at baseline or after three months of testosterone replacement (data not shown). Consequently, all subjects were included in whole-group analysis to increase statistical power. Five HDL-associated proteins changed significantly with testosterone replacement therapy (Table 3). HDL-associated paraoxonase 1 (PON1) and fibrinogen α chain (FGA) increased, whereas apolipoprotein A-IV (apoA-IV), apolipoprotein C-I (apoC-I), and paraoxonase 3 (PON3) decreased after three months of exogenous testosterone. After correction for multiple comparisons, the changes in PON1, apoA-IV, apoC-I, and FGA remained significant.

As lipid-lowering medications have been associated with changes in HDL protein composition (22), further analysis was conducted to determine the potential effects of statin therapy on observed changes in HDL-associated proteins. For the five proteins that changed with testosterone replacement, no significant differences were found in relative protein abundance among subjects on statin therapy and those not on lipid-lowering medications, either at baseline or after three months of testosterone therapy (supplementary Table II). No significant interactions were observed between statin therapy and testosterone replacement (supplementary Table III). Testosterone therapy most robustly contributed to the observed variance in the relative abundance of apoA-IV (17.8%, P = 0.008). Although the effect of statin use on apoC-I relative abundance did not achieve statistical significance (P = 0.08), the degree of variance attributable to statin use was greater than that associated with testosterone therapy (11.3% versus 3.9%, respectively). Statin use did not contribute significantly to the observed variance in PON1, apoA-IV, FGA, or PON3 relative abundance, accounting for <1.0% of the variance in each of these HDL-associated proteins. Thus, the changes in PON1, apoA-IV, and FGA both achieved statistical significance and appeared consequent specifically to testosterone exposure.

For the HDL-associated proteins that changed, no correlations were observed between the magnitude of changes in protein abundance and those in sex steroid levels (data not shown). After three months of testosterone therapy (but not at baseline), a negative correlation was found between total testosterone concentration and apoA-IV abundance (R = −0.48, P = 0.02) (data not shown).

Serum HDL cholesterol efflux

To determine whether changes in HDL protein cargo translated into altered HDL function, cholesterol efflux capacity was quantified by measuring the fraction of radiolabeled cholesterol released from macrophages to serum HDL (apoB-depleted serum). Lower efflux capacity as determined by this assay has been shown to correlate with the presence of CAD (7). No changes in serum HDL-mediated cholesterol efflux were evident after three months of testosterone replacement (baseline mean: 9.9 ± 1.4%, three-month mean: 9.9 ± 1.5%). The absence of change in efflux was apparent in both the subgroup and whole-group analyses. A positive correlation was observed between HDL-C and serum HDL cholesterol efflux as a trend at baseline, and it reached statistical significance after three months of testosterone replacement (Fig. 1A, B). No change in cholesterol efflux capacity was evident after correction for HDL-C (data not shown).

A trend toward a negative correlation between serum total testosterone and cholesterol efflux capacity was evident after three months of testosterone replacement therapy (R = −0.38, P = 0.07) (Fig. 2). At baseline, a negative correlation existed between apoA-IV relative abundance and cholesterol efflux capacity, but only after efflux was corrected for HDL-C (R = −0.58, P = 0.004) (Fig. 3A). The observed changes in both PON1 and PON3 relative abundance exhibited positive correlations with the changes in corrected cholesterol efflux capacity (Fig. 3B, C).


DISCUSSION

In the current study, we demonstrate that testosterone replacement therapy in older hypogonadal men alters the HDL proteome, supporting a role for sex steroids in determining HDL protein composition. However, this protein remodeling was not associated with a reduction in serum HDL-mediated cholesterol efflux from macrophages. These findings suggest that testosterone replacement in older hypogonadal men may not impair HDL ability to efflux cholesterol from macrophages but may affect other HDL-mediated functions.

Substantial controversy exists regarding the clinical indications for testosterone replacement therapy, particularly in the management of age-related hypogonadism. Reluctance to consider replacement stems in part from concern that testosterone might augment cardiovascular risk in men. Testosterone replacement in older men was associated with an increased incidence of cardiovascular events compared with placebo in a recent trial (1). However, the men in this study had significant mobility limitations and multiple comorbidities, possibly limiting the extension of these findings to healthy, aging men. In frail and healthy older men, testosterone replacement improves strength, physical function, and quality of life, and these benefits have been observed in the absence of an increased cardiovascular event rate (23). Further, epidemiologic data demonstrate increased CVD and mortality risk among men with low circulating testosterone levels (3, 4), and a disproportionately elevated risk of CVD is evident among men who have undergone androgen deprivation therapy for treatment of prostate cancer (24). These observations suggest that maintenance of eugonadal testosterone levels, in at least some populations of men, could exert health-promoting and possibly atheroprotective effects.

In our study, no changes in HDL-C or serum apoA-I were evident with the restoration of physiologic testosterone levels in older hypogonadal men. An HDL-C lowering effect of exogenous testosterone has been observed, although this finding is not universal (25) and is largely limited to studies in younger men and those that administered supraphysiologic or oral testosterone doses (26). The importance of route of administration is underscored by findings from direct comparison of oral and parenteral regimens of anabolic-androgenic steroids in male athletes (27). The absence of changes in HDL-C or serum apoA-I in our study consequently could reflect both the older study population and the use of transdermal administration. In postmenopausal women, oral hormone replacement therapies have been shown to alter HDL-C and serum apoA-I levels, cholesterol efflux capacity, and the abundance of HDL-associated proteins (2831). Therefore, oral regimens of testosterone replacement therapy could confer substantial changes in lipoprotein-related endpoints not captured in the current study.

Animal models and in vitro data demonstrate that modification of HDL-associated proteins can alter a variety of HDL functions, with associated effects on atherogenesis (32, 33). Further, enrichment of specific HDL-associated proteins has been identified in clinical populations with CVD and CVD risk factors (9, 10, 33, 34). It is therefore of interest that we found changes in three HDL-associated proteins that remained significant after correcting for multiple comparisons and assessing for interaction with concurrent statin use.

Previously, we demonstrated that testosterone deprivation in healthy, eugonadal men increased HDL-associated apoA-IV (19), data consistent with our current findings. The roles of apoA-IV in HDL-mediated cholesterol efflux and CVD remain unclear. In a transgenic mouse model, overexpression of human apoA-IV reduced atherosclerotic lesion area (32), and a common genetic variant of apoA-IV has been shown to exhibit enhanced cholesterol efflux from macrophages (35). ApoA-IV further may attenuate atherogenesis, in part due to its anti-oxidative activity (33). In apparent contrast, HDL-associated apoA-IV was enriched in a clinical population with CAD compared with matched controls (9).

Our data also demonstrate a significant increase in HDL-associated PON1 after testosterone replacement therapy. Recently, HDL particles isolated from patients with CAD were shown to stimulate less NO release from endothelial cells than HDL from healthy controls, a differential effect ascribed to PON1 damage mediated by products of lipid peroxidation (36, 37). PON1 has been proposed to scavenge lipid oxidation products, and apoA-I modified by these products loses its ability to promote cholesterol efflux through the ABCA1 pathway (31, 32); thus, PON1 may be critical for protecting HDL particles from oxidative damage. In future studies, it will be important to verify whether androgens affect PON1 abundance and activity and to determine whether testosterone replacement affects the capacity of HDL to stimulate endothelial cell NO production or scavenge oxidative byproducts. The positive correlations observed between changes in both PON1 and PON3 abundance and HDL-mediated cholesterol efflux further suggest the need for future studies to investigate the relationship between HDL-associated paraoxonase protein levels and HDL efflux capacity.

Finally, we found a significant increase in HDL-associated FGA. To date, no clear role has been identified for FGA in HDL function, atherogenesis, or CVD risk. The observed increase in PON3 relative abundance lost statistical significance after correction for multiple comparisons, and statin use may have played a confounding role in the changes evident in apoC-I abundance. ApoC-I is implicated strongly in triglyceride metabolism, as it can inhibit CETP and may regulate both hepatic lipase and LCAT activity (3840). VLDL apoC-I content has been positively correlated with fasting triglyceride concentrations and carotid plaque area (41), whereas HDL-mediated apoC-I transport rates were inversely correlated with plasma triglyceride levels (42). The apparent influence of statin therapy on apoC-I abundance in our study is supported by in vitro findings that statin treatment suppressed hepatocyte secretion of apoC-I (43). Nonetheless, subjects who were not on statin therapy also exhibited decreases in HDL-associated apoC-I, and changes in serum apoC-I have been observed consequent to hormone replacement therapy in women (28). Thus, the possible regulation of both apoC-I and PON3 by sex steroids warrants further investigation in larger studies. Finally, our current analytical strategy has limited sensitivity for detecting changes in lower abundance proteins that are known to play pivotal roles in determining HDL composition and function. Such proteins include CETP, which was detected only in two subjects, and will require targeted investigation employing methods of absolute protein quantification. Similarly, as for other HDL-associated enzymes, metrics that assay enzymatic activity in addition to protein levels will be crucial for better delineating the relationship between sex steroids and HDL.

As testosterone is converted to estradiol by aromatization, exogenous testosterone therapy conferred concurrent increases in serum estradiol. Our study therefore cannot discriminate between androgen- and estrogen-mediated effects underlying the observed changes in HDL protein cargo. The absence of differences noted between men who received testosterone alone and those who also received dutasteride indicates that the observed changes were not contingent on circulating levels of DHT. Furthermore, the absence of differences between the two treatment groups suggests that the modestly higher serum estradiol levels evident among men who received dutasteride did not confer substantial effects on HDL protein composition. However, the men who received dutasteride had higher estradiol concentrations at baseline, rendering the net changes in serum estradiol comparable in both treatment groups. This baseline difference likely is consequent to our small sample size and underscores further the need for dedicated investigation of the respective effects of androgens and estrogens on the HDL proteome.

Many lines of evidence indicate that HDL mediates pleiotropic effects, suggesting the importance of assessing HDL function in the prediction of CVD risk (4446). A principal means by which HDL is thought to confer atheroprotection is reverse cholesterol transport, whereby HDL accepts cholesterol from peripheral tissues, including macrophages, and transports it to the liver for excretion (11). This unloading of lipid from macrophages could reduce foam cell formation and thereby attenuate atherogenesis. Notably, Khera et al. (7) have developed an assay of serum HDL-mediated cholesterol efflux from macrophages and demonstrated a significant, negative correlation between efflux capacity and extant CAD in a cross-sectional analysis. In our population of older hypogonadal men, we found no significant change in efflux capacity consequent to testosterone replacement. The absence of change in HDL-C partially may underlie the absence of change in cholesterol efflux capacity, as these have been shown to correlate significantly (7). Alternatively, this negative finding might reflect our limited sample size or the concurrent increases in serum androgen and estrogen concentrations, which could produce differential or offsetting effects on HDL-C and HDL function. Accordingly, further study is required to determine whether the selective restoration of normal physiologic levels of circulating androgens or estrogens affects HDL cholesterol efflux capacity. Notably, cholesterol efflux represents only one of a growing number of functions now recognized for HDL particles (12, 33, 47), and continued research is warranted to determine how testosterone replacement may affect additional HDL-mediated functions.

Our findings indicate that in older hypogonadal men, the restoration of testosterone levels to those found in healthy young men alters HDL protein composition but does not appear to change the cholesterol efflux capacity of serum HDL. Testosterone replacement also conferred significant increases in HDL-associated PON1 and FGA and a decrease in apoA-IV. Given the absence of a functional correlate, the net effects of these changes on HDL function or CVD risk remain unclear. Our findings therefore underscore the need for assessment of additional HDL functions after exogenous testosterone therapy but suggest that sterol efflux to HDL is not impaired by testosterone replacement. Further, our findings indicate the need for continued investigation of both the roles of individual HDL-associated proteins in atherogenesis and the utility of various metrics of HDL function for predicting cardiovascular risk. Such broadened understanding is essential to better interpret the role of sex steroids in cholesterol metabolism and attendant risk of CVD in men.


Supplementary Material Supplemental Data

Notes

gloss1

Abbreviations:
BMI body mass index
CAD coronary artery disease
CETP cholesterol ester transfer protein
CVD cardiovascular disease
DHEA dehydroepiandrosterone
DHT dihydrotestosterone
FGA fibrinogen alpha chain
FSH follicle-stimulating hormone
HDL-C HDL cholesterol
LH luteinizing hormone
NO nitric oxide
PON1/3 paraoxonase 1/3
S1P sphingosine-1 phosphate
SHBG sex hormone binding globulin
T only 7.5 g transdermal 1% testosterone gel with daily oral placebo
T+D 7.5 g transdermal 1% testosterone gel with 0.5 mg dutasteride

This work was supported by National Institutes of Health Grants RO1-AG-037603, U54-HD-42454, P50-CA-097186, DK-017047, T32-DK-007247 (K. B. R.), P30-DK-035816 (T. V.), R01-HL-089504 (T. V.), P30-DK-017047, P01-HL-112625 (J. W. H.), R01-HL-086798 (J. W. H.), and P01-HL-092969 (J. W. H.); by the Department of Veterans Affairs Puget Sound Health Care System (A. M. M.); and by American Heart Association Grant 083-0231N (T. V.). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. Transdermal placebo and testosterone gels were provided by Abbott Laboratories (formerly Solvay Pharmaceuticals), and dutasteride and oral placebo were provided by GlaxoSmithKline, neither of which had any input into the study design, analyses, or manuscript preparation.

[S]The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of three tables.

REFERENCES
1.. Basaria S.,Coviello A. D.,Travison T. G.,Storer T. W.,Farwell W. R.,Jette A. M.,Eder R.,Tennstedt S.,Ulloor J.,Zhang A.,et al. Year: 2010Adverse events associated with testosterone administration. N. Engl. J. Med.363: 109–12220592293
2.. Wu F. C.,von Eckardstein A.. Year: 2003Androgens and coronary artery disease. Endocr. Rev.24: 183–21712700179
3.. Laughlin G. A.,Barrett-Connor E.,Bergstrom J.. Year: 2008Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metab.93: 68–7517911176
4.. Vikan T.,Schirmer H.,Njolstad I.,Svartberg J.. Year: 2009Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study. Eur. J. Endocrinol.161: 435–44219542243
5.. Barter P. J.,Caulfield M.,Eriksson M.,Grundy S. M.,Kastelein J. J.,Komajda M.,Lopez-Sendon J.,Mosca L.,Tardif J. C.,Waters D. D.,et al. Year: 2007Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med.357: 2109–212217984165
6.. AIM-HIGH InvestigatorsYear: 2011The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am. Heart J.161: 538–54321392609
7.. Khera A. V.,Cuchel M.,de la Llera-Moya M.,Rodrigues A.,Burke M. F.,Jafri K.,French B. C.,Phillips J. A.,Mucksavage M. L.,Wilensky R. L.,et al. Year: 2011Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med.364: 127–13521226578
8.. Heinecke J.. Year: 2011HDL and cardiovascular-disease risk--time for a new approach?N. Engl. J. Med.364: 170–17121226584
9.. Vaisar T.,Mayer P.,Nilsson E.,Zhao X. Q.,Knopp R.,Prazen B. J.. Year: 2010HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin. Chim. Acta.411: 972–97920307520
10.. Vaisar T.,Pennathur S.,Green P. S.,Gharib S. A.,Hoofnagle A. N.,Cheung M. C.,Byun J.,Vuletic S.,Kassim S.,Singh P.,et al. Year: 2007Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest.117: 746–75617332893
11.. Rader D. J.,Alexander E. T.,Weibel G. L.,Billheimer J.,Rothblat G. H.. Year: 2009The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res.50(Suppl.): S189–S19419064999
12.. Gordon S. M.,Hofmann S.,Askew D. S.,Davidson W. S.. Year: 2011High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol. Metab.22: 9–1521067941
13.. Movva R.,Rader D. J.. Year: 2008Laboratory assessment of HDL heterogeneity and function. Clin. Chem.54: 788–80018375481
14.. Mineo C.,Shaul P. W.. Year: 2011PON-dering differences in HDL function in coronary artery disease. J. Clin. Invest.121: 2545–254821701074
15.. Page S. T.,Hirano L.,Gilchriest J.,Dighe M.,Amory J. K.,Marck B. T.,Matsumoto A. M.. Year: 2011Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J. Urol.186: 191–19721575967
16.. Vermeulen A.,Verdonck L.,Kaufman J. M.. Year: 1999A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab.84: 3666–367210523012
17.. Guy J.,Ogden L.,Wadwa R. P.,Hamman R. F.,Mayer-Davis E. J.,Liese A. D.,D'Agostino R. Jr,Marcovina S.,Dabelea D.. Year: 2009Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care.32: 416–42019092167
18.. Agger S. A.,Marney L. C.,Hoofnagle A. N.. Year: 2010Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. Clin. Chem.56: 1804–181320923952
19.. Rubinow K. B.,Tang C.,Hoofnagle A. N.,Snyder C. N.,Amory J. K.,Heinecke J. W.,Page S. T.. Year: 2012Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men. Steroids.77: 454–46022266332
20.. Tukey J. W.,Ciminera J. L.,Heyse J. F.. Year: 1985Testing the statistical certainty of a response to increasing doses of a drug. Biometrics.41: 295–3014005384
21.. Karlsson H.,Leanderson P.,Tagesson C.,Lindahl M.. Year: 2005Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics.5: 1431–144515761960
22.. Green P. S.,Vaisar T.,Pennathur S.,Kulstad J. J.,Moore A. B.,Marcovina S.,Brunzell J.,Knopp R. H.,Zhao X. Q.,Heinecke J. W.. Year: 2008Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation.118: 1259–126718765395
23.. Srinivas-Shankar U.,Roberts S. A.,Connolly M. J.,O'Connell M. D.,Adams J. E.,Oldham J. A.,Wu F. C.. Year: 2010Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab.95: 639–65020061435
24.. Keating N. L.,O'Malley A. J.,Freedland S. J.,Smith M. R.. Year: 2010Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J. Natl. Cancer Inst.102: 39–4619996060
25.. Ozata M.,Yildirimkaya M.,Bulur M.,Yilmaz K.,Bolu E.,Corakci A.,Gundogan M. A.. Year: 1996Effects of gonadotropin and testosterone treatments on Lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J. Clin. Endocrinol. Metab.81: 3372–33788784099
26.. Shabsigh R.,Katz M.,Yan G.,Makhsida N.. Year: 2005Cardiovascular issues in hypogonadism and testosterone therapy. Am. J. Cardiol.96: 67M–72M15979436
27.. Hartgens F.,Rietjens G.,Keizer H. A.,Kuipers H.,Wolffenbuttel B. H.. Year: 2004Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br. J. Sports Med.38: 253–25915155420
28.. Chiuve S. E.,Martin L. A.,Campos H.,Sacks F. M.. Year: 2004Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women. J. Clin. Endocrinol. Metab.89: 2207–221315126543
29.. Ulloa N.,Arteaga E.,Bustos P.,Duran-Sandoval D.,Schulze K.,Castro G.,Jauhiainen M.,Fruchart J. C.,Calvo C.. Year: 2002Sequential estrogen-progestin replacement therapy in healthy postmenopausal women: effects on cholesterol efflux capacity and key proteins regulating high-density lipoprotein levels. Metabolism.51: 1410–141712404190
30.. von Eckardstein A.,Crook D.,Elbers J.,Ragoobir J.,Ezeh B.,Helmond F.,Miller N.,Dieplinger H.,Bennink H. C.,Assmann G.. Year: 2003Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux. Clin. Endocrinol. (Oxf.).58: 49–5812519412
31.. Hughes T. A.,Pace D. T.,Ke R. W.,Tolley E. A.,Qureshi N.,Stentz F.. Year: 2004Lipoprotein compositional changes with combination hormone therapy (conjugated estrogen and medroxyprogesterone) in African American women. Endocr. Pract.10: 179–18615310534
32.. Duverger N.,Tremp G.,Caillaud J. M.,Emmanuel F.,Castro G.,Fruchart J. C.,Steinmetz A.,Denefle P.. Year: 1996Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science.273: 966–9688688083
33.. Kontush A.,Chapman M. J.. Year: 2006Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev.58: 342–37416968945
34.. Hoofnagle A. N.,Wu M.,Gosmanova A. K.,Becker J. O.,Wijsman E. M.,Brunzell J. D.,Kahn S. E.,Knopp R. H.,Lyons T. J.,Heinecke J. W.. Year: 2010Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. Arterioscler. Thromb. Vasc. Biol.30: 2528–253420847305
35.. Gomaraschi M.,Putt W. E.,Pozzi S.,Iametti S.,Barbiroli A.,Bonomi F.,Favari E.,Bernini F.,Franceschini G.,Talmud P. J.,et al. Year: 2010Structure and function of the apoA-IV T347S and Q360H common variants. Biochem. Biophys. Res. Commun.393: 126–13020117098
36.. Besler C.,Heinrich K.,Rohrer L.,Doerries C.,Riwanto M.,Shih D. M.,Chroni A.,Yonekawa K.,Stein S.,Schaefer N.,et al. Year: 2011Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest.121: 2693–270821701070
37.. Shao B.,Pennathur S.,Pagani I.,Oda M. N.,Witztum J. L.,Oram J. F.,Heinecke J. W.. Year: 2010Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J. Biol. Chem.285: 18473–1848420378541
38.. Rouhani N.,Young E.,Chatterjee C.,Sparks D. L.. Year: 2008HDL composition regulates displacement of cell surface-bound hepatic lipase. Lipids.43: 793–80418670796
39.. Conde-Knape K.,Bensadoun A.,Sobel J. H.,Cohn J. S.,Shachter N. S.. Year: 2002Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. J. Lipid Res.43: 2136–214512454276
40.. Meyers N. L.,Wang L.,Small D. M.. Year: 2012Apolipoprotein C–I binds more strongly to phospholipid/triolein/water than triolein/water interfaces: a possible model for inhibiting cholesterol ester transfer protein activity and triacylglycerol-rich lipoprotein uptake. Biochemistry.51: 1238–124822264166
41.. Hansen J. B.,Fernandez J. A.,Noto A. T.,Deguchi H.,Bjorkegren J.,Mathiesen E. B.. Year: 2011The apolipoprotein C-I content of very-low-density lipoproteins is associated with fasting triglycerides, postprandial lipemia, and carotid atherosclerosis. J. Lipids.2011: 27106221776394
42.. Cohn J. S.,Batal R.,Tremblay M.,Jacques H.,Veilleux L.,Rodriguez C.,Mamer O.,Davignon J.. Year: 2003Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism. J. Lipid Res.44: 1976–198312867543
43.. Bouchard C.,Dubuc G.,Davignon J.,Bernier L.,Cohn J. S.. Year: 2005Post-transcriptional regulation of apoC-I synthesis and secretion in human HepG2 cells. Atherosclerosis.178: 257–26415694932
44.. Shao B.,Oda M. N.,Oram J. F.,Heinecke J. W.. Year: 2010Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem. Res. Toxicol.23: 447–45420043647
45.. Barter P. J.,Nicholls S.,Rye K. A.,Anantharamaiah G. M.,Navab M.,Fogelman A. M.. Year: 2004Antiinflammatory properties of HDL. Circ. Res.95: 764–77215486323
46.. Yvan-Charvet L.,Wang N.,Tall A. R.. Year: 2010Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler. Thromb. Vasc. Biol.30: 139–14319797709
47.. Suzuki M.,Pritchard D. K.,Becker L.,Hoofnagle A. N.,Tanimura N.,Bammler T. K.,Beyer R. P.,Bumgarner R.,Vaisar T.,de Beer M. C.,et al. Year: 2010High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation.122: 1919–192720974999

Figures

[Figure ID: fig1]
Fig. 1. 

A positive correlation between HDL-C and HDL cholesterol efflux capacity was evident as a trend at baseline (A) and achieved significance after three months of testosterone replacement (B).



[Figure ID: fig2]
Fig. 2. 

No correlation was evident between serum testosterone and efflux capacity at baseline (A), but a negative correlation between efflux capacity and serum testosterone levels existed as a trend after three months of testosterone replacement (B).



[Figure ID: fig3]
Fig. 3. 

A negative correlation existed between corrected efflux capacity and apoA-IV relative abundance at baseline (A), and positive correlations were observed between changes in corrected efflux capacity and changes in PON1 (B) and PON3 (C) relative abundance after three months of testosterone replacement.



Tables
[TableWrap ID: tbl1] TABLE 1. 

Hormone concentrations at baseline and after three months of testosterone replacement


Baseline Three Months Baseline Three Months Baseline Three Months
Both groups (n = 23) T+D (n = 12) T-only (n = 11)
Total testosterone (ng/dl) 222 ± 81 597 ± 307c 226 ± 81 576 ± 254c 219 ± 85 621 ± 368c
Free testosterone (ng/dl) 4.5 ± 1.7 14.3 ± 6.2c 4.9 ± 2.0 14.2 ± 6.9c 4.1 ± 1.3 14.4 ± 5.6c
Estradiol (pg/ml) 15.3 ± 9.7 25.0 ± 10.9c 17.0 ± 9.8 28.4 ± 11.5b 13.5 ± 9.8 21.3 ± 9.3a
DHT (ng/dl) 24 ± 10 95 ± 127a 25 ± 9 13 ± 7b 24 ± 11 184 ± 137c
DHEA (ng/ml) 1.0 ± 0.6 1.3 ± 1.2 1.2 ± 0.6 1.4 ± 1.1 0.9 ± 0.5 1.2 ± 1.3
SHBG (μg/ml) 3.2 ± 1.2 2.9 ± 1.5 2.8 ± 1.3 2.9 ± 1.2 3.5 ± 1.7 3.0 ± 1.8

Values expressed as mean ± SD.

aP < 0.05.

bP < 0.01.

cP < 0.001.


[TableWrap ID: tbl2] TABLE 2. 

Fasting lipid concentrations at baseline and after three months of testosterone replacement


Baseline Three Months Baseline Three Months Baseline Three Months
Both groups (n = 23) T+D (n = 12) T-only (n = 11)
Total cholesterol (mg/dl) 187 ± 46 181 ± 40 187 ± 44 189 ± 44 186 ± 51 171 ± 36
VLDL cholesterol (mg/dl) 52 ± 40 50 ± 39 54 ± 44 61 ± 49 50 ± 38 39 ± 21
LDL-C (mg/dl) 101 ± 41 100 ± 36 94 ± 32 102 ± 41 108 ± 50 97 ± 33
HDL-C (mg/dl) 37 ± 11 35 ± 11 39 ± 11 36 ± 12 36 ± 11 34 ± 11
Triglycerides (mg/dl) 260 ± 202 251 ± 197 270 ± 220 304 ± 247 249 ± 191 193 ± 37
ApoA-I (mg/dl) 164 ± 28 157 ± 30 168 ± 22 165 ± 29 160 ± 34 150 ± 31

Values expressed as mean ± SD.


[TableWrap ID: tbl3] TABLE 3. 

Relative abundance of HDL-associated proteins at baseline and after three months of testosterone therapy


Protein Baseline Three Months P
ApoA-I 1801 ± 206 1862 ± 244 0.51
ApoA-II 682 ± 72 672 ± 88 0.51
PON1 153 ± 35 177 ± 45 0.022a
ApoA-IV 157 ± 64 116 ± 30 0.016a
SAA4 130 ± 19 124 ± 22 0.07
ApoE 116 ± 20 119 ± 28 0.78
ApoC-II 119 ± 27 111 ± 30 0.14
ApoC-I 91 ± 17 85 ± 14 0.024a
ApoD 66 ± 12 68 ± 14 0.71
ApoM 61 ± 13 68 ± 15 0.09
FGA 24 ± 19 42 ± 23 0.023a
PON3 18 ± 5 22 ± 7 0.03

Values expressed as mean spectral count ± SD. SAA4, serum amyloid A4. Bold font indicates P < 0.05.

aP < 0.029.



Article Categories:
  • Patient-Oriented and Epidemiological Research

Keywords: cardiovascular disease, lipoproteins, lipids, atherosclerosis, androgens.

Previous Document:  Lack of "immunological fitness" during fasting in metabolically challenged animals.
Next Document:  Differential signature of fecal microRNAs in patients with pancreatic cancer.